What is the prevalence of Progressive Supranuclear Palsy?

Progressive Supranuclear Palsy (PSP) is estimated to affect approximately 3 to 6 per 100,000 individuals, classifying it as a rare neurodegenerative disorder.

Epidemiological Data and Incidence

While precise global figures are difficult to establish, the incidence of Progressive Supranuclear Palsy is estimated at roughly 0.3 to 1.1 per 100,000 person-years. Because Progressive Supranuclear Palsy is frequently misdiagnosed as Parkinson’s disease or other atypical parkinsonian syndromes in its early stages, these numbers likely underestimate the true burden of the condition. Most clinical data suggests that the prevalence increases significantly with age, particularly in those over 60.

Demographics and Onset

Progressive Supranuclear Palsy is a disease primarily of mid-to-late adulthood, with an average age of onset typically between 60 and 70 years; it is virtually never diagnosed in pediatric populations. While some studies suggest a slight male preponderance, the condition affects both men and women across various ethnic and geographic backgrounds without clear evidence of a specific regional cluster. There is no definitive evidence that race or geography significantly alters the risk of developing this condition.

Challenges in Accurate Reporting

The primary challenge in gathering accurate statistics for Progressive Supranuclear Palsy remains the clinical overlap with other tauopathies. Early symptoms—such as loss of balance or slurred speech—are often attributed to other conditions, leading to delays in diagnosis. This is where the Progressive Supranuclear Palsy community at DiseaseMaps.org provides invaluable real-world perspective; by connecting hundreds of patients, the platform helps highlight the lived experience and diagnostic journeys that official clinical registries sometimes miss. These patient-reported data points serve as a vital supplement to traditional epidemiological studies, offering insights into the true prevalence of the disease.

Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• CurePSP: Foundation for PSP and CBD research and care